拉米夫定联合阿德福韦酯治疗HBeAg阳性失代偿期乙肝肝硬化的临床效果

Clinical effect experience of lamivudine combined with adefovir dipivoxil in the treatment of patients with hepatitis B cirrhosis and decompensated HBeAg positive

目的:探讨拉米夫定联合阿德福韦酯治疗HBeAg阳性失代偿期乙肝肝硬化的临床效果。方法:收治乙肝肝硬化的HBeAg阳性失代偿期患者50例,分为两组。对照组先使用拉米夫定,后使用阿德福韦酯,研究组在初始治疗时即联合使用拉米夫定及阿德福韦酯,比较两组临床疗效。结果:研究组HBeAg血清转阴率、Child-Push评分、HBV-DNA载量均优于对照组(P<0.05)。结论:初始治疗时拉米夫定联合阿德福韦酯治疗HBeAg阳性失代偿期乙肝肝硬化患者的临床效果显著。

Objective:To explore the clinical curative effect of lamivudine combined with adefovir dipivoxil in the treatment of patients with hepatitis B cirrhosis and decompensated HBeAg positive.Methods:50 cases of patients with hepatitis B cirrhosis and decompensated HBeAg positive were divided into two groups.The control group was given adefovir dipivoxil after lamivudine,and the research group was given lamivudine combined with adefovir dipivoxil as the initial treatment.The clinical curative effect of two groups was compared.Results:The HBeAg seroconversion rate,Child-Push score,HBV-DNA of the research group were better than those of the control group(P<0.05).Conclusion:Lamivudine combined with adefovir dipivoxil as the initial treatment for patients with hepatitis B cirrhosis and decompensated HBeAg positive had significant clinical curative effect.